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Underlying Pathophysiology 
Bulbar Symptoms: 
• Eye muscle weakness  
• Ptosis, double vision, blurring 
• Slurred speech 
• Stuttering  
• Low endurance of mastication 
• Droop of corners of mouth 
• Facial weakness/droop 
• Dysphagia 
Trunk/Limb Symptoms: 
• Proximal symptoms 
• Weak neck muscles: head drooping 
• Arms, shoulder weakness 
• Wrist, finger weakness 
• Ankle weakness 
 
 
 
  
 
The hallmark sign of MG is fluctuating 
muscle weakness and fatigue that is 
exacerbated with activity and improves with 
rest.  Weakness is typically least 
bothersome in the morning, when 
acetylcholine stores are highest, and 
symptoms worsen as the day progresses 
(Abbott, 2010, p. 471).  
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       The estimated amount of MG patients 
has more than doubled in the last twenty 
years (Avidan et al., 2014, p. 146).  This 
could be because of many factors including 
better diagnosis, improved treatment, and 
an increasing aging population.  The 
average age of onset for females is 20-30 
years; the average age of onset for males is 
60-80 years.  This is significant information 
to consider because of the increasing aging 
population.  It is probable that because 
people are living longer, there is an increase 
in the amount of people experiencing the 
onset of MG. 
       Although there is plenty still unknown, 
MG is considered to be one of the best 
understood of all autoimmune diseases.  
Before improved corticosteroid therapies 
were developed, one third of patients 
diagnosed with myasthenia gravis died 
(Abbott, 2010, p. 470).  With continued 
improvements in research, diagnosis, and 
treatment the prognosis is good in terms of 
quality of life, daily functions, and survival 
(Sieb, 2013, p. 408). 
         Understanding the pathophysiology is 
of extreme importance so diagnosis is 
completed quicker and more accurately, 
and treatment options are performed.  As 
mentioned previously, it is now known that 
MG can be divided into subcategories of 
antibody specificity.  Understanding exactly 
where and how the antibodies are impeding 
function at the NMJ leads to more accurate 
treatment options and prolonged periods of 
remission.   
        Knowing the significance of 
pathophysiology of MG is crucial because 
these patients are susceptible to myasthenic 
crisis, a life threatening condition.  During 
myasthenic crisis, the respiratory and 
accessory muscles are significantly 
weakened as well as the diaphragm (Weeks, 
2012, p. 33).  These patients often require a 
mechanical ventilator until the exacerbation 
subsides.  Although a critical condition, with 
improvements in knowledge about the 
disease and proper treatments, mortality 
from myasthenic crisis alone is less than 
5% (Weeks, 2012, p. 32). 
Qualitative research also assists in 
understanding the significance of the 
disease process.  “Incorporating the 
patient’s perspective provides invaluable 
information regarding which impairments 
are most relevant to patients as well as 
patterns of impairment” (Barnett, Bril, 
Kapral, Kulkarni, Davis, 2014, p. 1).  A 
patient may verbalize difficulty with daily 
activities due to weakness but may have a 
one time clinical presentation displaying the 
opposite.  Concerning MG, this is the 
hallmark sign of fatigability.  A solid 
knowledge base of the pathological 
processes taking place will only enhance the 
understanding of the patient’s perspective 
of symptoms, thus, leading to better 
treatment and care plans. 
        Myasthenia gravis (MG) is a chronic 
autoimmune neuromuscular disease 
characterized by ocular, bulbar, facial, 
and skeletal muscle weakness due to a 
defect in the transmission of nerve to 
muscle impulses at the neuromuscular 
junction (Mestecky, 2013, p. 110). 
        Approximately 14-20 in 100,000 
people are diagnosed with myasthenia 
gravis in the United States (Leis, Moore, 
Kofler, Beric, De Visser, 2014, p. 112).  
Typically, diagnosis occurs in middle-
aged adults with women generally 
acquiring the disease at a younger age 
than men (Mestecky, 2013, p. 110).  MG 
has the potential to greatly affect the 
quality of life of a patient. 
        Although the disease may go into 
remission for any given amount of time, 
there is currently no known cure for 
myasthenia gravis.  Patients experience 
varying degrees of symptoms, however, 
there are several treatment options 
available to help those with MG decrease 
symptoms and lead full lives.  
 
Significance 
        MG is an uncommon disease that 
can greatly affect the lives of the 
patient and their family members.  
Patients may experience myasthenic 
crisis, which is life threatening, 
however, it is important to remember 
that they continue living with the 
disease and its effects every day.  
Family Nurse Practitioners must 
design an individualized care plan to 
treat and manage symptoms in a 
patient’s every day life.  It is also 
imperative to note that official 
diagnosis of MG may be delayed in 
many patients because the symptoms 
vary in each case.  It is important to 
have a solid knowledge base regarding 
this disease in order to adequately 
diagnose patients in a timely manner.  
This is a manageable disease but can 
become life threatening, therefore, 
earlier recognition and treatment is 
essential.  
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        The highly variable symptom presentation of 
myasthenia gravis can pose considerable challenges 
to accurate diagnosis.  Because of the similarities of 
symptoms with many other neurological diseases 
and disorders, providers may unknowingly give a 
wrong diagnosis.  Physical examination, thorough 
neurological assessment, and detailed medical 
history are of utmost important.  Providers, such as 
nurse practitioners, must have a substantial 
understanding of MG and its presentation in order to 
differentiate other diagnoses.  It is now becoming 
possible to identify the antigenic target in almost all 
cases of MG, consequently leading to more specific 
care plans and focused therapies (Lewis, 2013, p. 
97).  The earlier MG is recognized and treatment 
started, the better the outcomes and quality of life for 
the patient. 
         Education plays a 
huge role in nursing care for those affected by MG.  
Knowing the disease process, how it affects ones 
body, and ways to improve or avoid symptoms is of 
utmost importance.  Nursing care plays a primary 
role in educating patients on how to enhance their 
daily lives while living with a chronic condition.  
Because of the increase in diagnosis and aging 
population as previously stated, providers are highly 
likely to come in contact with a patient diagnosed 
with MG during their career.  Understanding the 
pathophysiology as well as the patient’s perception of 
the disease and its symptoms will only serve to 
improve overall care and clinical decision-making. 
Implications for Nursing Care 
        Myasthenia gravis was once an 
unknown neurological disease with poor 
outcomes.  However, with continuous 
advanced research, it is now one of the 
most understood autoimmune diseases 
today.  Although it is still a serious 
condition, patients with this diagnosis are 
expected to have longer survival rates and 
increased quality of daily life activities.  
Nurse practitioners are providers that will 
have contact with these patients very 
frequently and keen assessment skills are 
needed for accurate diagnosis.  Continuous 
research and treatment plans may lead to 
not only longer periods of remission, but 
possibly a cure.  
In a normally functioning 
neuromuscular system, transmission of nerve 
impulses to the muscle occurs at the 
neuromuscular junction (NMJ).  The 
neurotransmitter acetylcholine is released 
from the motor neurons, crosses the synaptic 
cleft, and attaches to the acetylcholine 
receptor on the muscle fibers, consequently 
generating a muscle contraction.  This 
mechanism is altered in patients with 
myasthenia gravis. 
Myasthenia gravis is a relatively rare, 
autoimmune, neuromuscular disorder.  “MG is 
a B-cell driven, T-cell dependent, complement 
and antibody-mediated disease, due to 
autoantibodies directed against molecules at 
the neuromuscular junction” (Avidan, Panse, 
Berrih-Aknin, Miller, 2014, p. 146).   These 
antibodies are directed against proteins 
concentrated at the NMJ, which include 
nicotinic acetylcholine receptor (AChR), the 
muscle-specific kinase (MuSK), or the 
lipoprotein-related protein 4 (LRP4).  The 
most common antibody found in MG patients 
is against AChR (Kusner, Ciesielski, Marx, 
Kaminski, Fenstermaker, 2014, p. 1).  “The 
binding of anti-AChR antibodies to their target 
impairs neuromuscular transmission by 
complement-mediated destruction of the 
postsynaptic membrane” (Avidan et al., 2014, 
p. 146).   
The thymus gland is the chief organ for 
immunological self-tolerance and usually 
decreases in size and is replaced with fat as 
one ages (Weeks, 2012, p. 31).  Many patients 
with MG have thymus abnormalities including 
hyperplasia or thymoma, which may play a 
role in disease initiation.  These mechanisms 
include the expression of self-antigens by 
thymoma cells and impairment of 
autoreactive T lymphocytes (Ha & Richman, 
2014, p. 652).  The exact role of thymus in MG 
is not fully understood, however, researchers 
suspect that viruses or bacteria may trigger 
this autoimmune response. 
Patients with MG experience cycles of 
remission and exacerbation.  There are many 
factors thought to exacerbate the symptoms 
associated with MG.  These include pregnancy, 
emotional stress, thyroid disease, 
menstruation cycle, and viral or bacterial 
illness particularly upper respiratory 
infection (Abbott, 2010, p. 470).   
 
